Orange Book product · Brand (NDA)
CLEVIPREX
CLEVIDIPINE
At a glance
Nov 08, 2013
Approved
Brand (NDA)
Application
Not listed
TE code
3
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Nov 08, 2013
12 yr 10 mo ago
Today
Patent 10010537 expires
Listed drug product patent expiration.
Oct 10, 2031
in 5 yr 5 mo
Patent 11103490 expires
Listed drug product patent expiration.
Oct 10, 2031
in 5 yr 5 mo
Patent 8658676 expires
Listed drug product patent expiration.
Oct 10, 2031
in 5 yr 5 mo
Pharmaceutical detail
Active ingredient
CLEVIDIPINE
Strength
125MG/250ML (0.5MG/ML)
Dosage form
EMULSION
Route
INTRAVENOUS
TE code
Not listed
Application
NDA 022156
Product number
003
Marketing status
DISCN
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Listed patents (3)
| Patent | Expires | In | Type |
|---|---|---|---|
| 10010537 | Oct 10, 2031 | in 5 yr 5 mo | Product |
| 11103490 | Oct 10, 2031 | in 5 yr 5 mo | Product |
| 8658676 | Oct 10, 2031 | in 5 yr 5 mo | Product |

